Karyopharm Announces New Interim Phase 2 Selinexor Data in Myelofibrosis Selected for Oral Presentation at the American Society of Hematology 2021 Annual Meeting and ExpositionPRNewsWire • 11/04/21
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business HighlightsPRNewsWire • 11/03/21
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/25/21
Karyopharm Announces Dosing of First Patient in a Phase 2 Study Investigating Oral Eltanexor in HMA Refractory Myelodysplastic SyndromePRNewsWire • 10/21/21
Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in ChinaPRNewsWire • 08/24/21
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock OptionsZacks Investment Research • 08/20/21
Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial ResultsPRNewsWire • 08/05/21
Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and MyelofibrosisPRNewsWire • 07/28/21
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic MalignanciesPRNewsWire • 07/14/21
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)PRNewsWire • 07/06/21
Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 MillionPRNewsWire • 06/24/21
Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood DisorderBenzinga • 06/09/21
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual CongressPRNewsWire • 06/09/21